Myriad

Total revenues for the period were $154.6 million, down from $195.1 million but beating the consensus Wall Street estimate.

Of the 32 companies in the index, 27 firms saw their stock prices increase, while 5 saw their share prices decline.

News items for the in vitro diagnostics industry for the week of Jan. 18, 2021.

Among firms presenting on the first day, Roche provided insights into its COVID-19 testing business, and Guardant said it plans to launch a comprehensive tissue sequencing assay. 

The firm also provided preliminary revenues of $950 million for Q4 and reinstated guidance of $3.79 billion to $3.88 billion for 2021.

Not every company in the 360Dx Index had significant gains, but multiple companies saw their share prices double. 

The changes follow a strategic review and are part of the company's previously announced plans for growing its revenues and reducing costs. 

Quidel and Accelerate Diagnostics had the biggest declines in their share prices as the Index lagged behind the broader markets.

A deal with Burning Rock will allow the test to be used in trials and clinics in China, and Myriad will license its technology to French and German pathology labs.